ESHAP for primary cutaneous T-cell lymphomas: Efficacy and tolerance in 11 patients

Hematology Journal

Volumn 5, Issue 7, 2005, Pages 553-558

  Mebazaa, Amel ^a   Dupuy, Alain ^a   Rybojad, Michel ^a   Mouly, Frédéric ^a   Moulonguet, Isabelle ^a   Vignon Pennamen, Marie Dominique ^b   Rivet, Jacqueline ^b   Janin, Anne ^b   Lebbé, Celeste ^a   Dubertret, Louis ^a   Morel, Patrice ^a   Bachelez, Hervé ^a   Brice, Pauline ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chemotherapy; Cutaneous T cell lymphomas; Survival

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; ONDANSETRON; PREDNISONE; PSORALEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINDESINE;

ACUTE PANCREATITIS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEARING LOSS; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NEUTROPENIA; PERIPHERAL NEUROPATHY; PUVA; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; CISPLATIN; CYTARABINE; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044388715     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200570     Document Type: Article

References (19)

1. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
2. Van Doorn R, Van Haselen CW, Van Voorst Vader PC, Geerts ML, Heule F, De Rie M et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-510.
3. Kaye FJ, Bunn Jr PA, Steinberg SM, Stocher JL, Ihde DC, Fischmann AB et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-1790.
4. Ozturk MA, Barista I, Altundag MK, Turker A, Yalcin S, Celik I et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy 2002; 48: 252-258.
5. Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, Guitart J. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2152-2168.
6. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86: 1368-1376.
7. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272.
8. Bunn Jr PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JC, Matthews TJ et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93: 223-230.
9. Fierro MT, Doveil GC, Quaglino P, Savoia P, Verrone A, Bernengo MG. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997; 194: 268-272.
10. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998; 31: 583-588.
11. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001; 144: 1010-1015.
12. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000; 42: 40-46.
13. Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10: 593-595.
14. Petit J, Boque C, Cancelas JA, Sarra J, Munoz J, Garcia G et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilization regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999; 34: 119-127.
15. Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999; 33: 543-550.
16. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
17. 2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-282.
18. Bunn Jr PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
19. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clopisson G et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181-186.